<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35604631</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-0100</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Endocrine</Title>
          <ISOAbbreviation>Endocrine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Resistant prolactinomas: a case series of 26 patients.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12020-022-03080-1</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Prolactin (PRL)-secreting tumors are the most common functional pituitary adenomas. They usually respond to dopamine agonist (DA) treatment, with PRL normalization and adenoma shrinkage. Our aim was to characterize patients with prolactinoma resistant to DA treatment.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective case series included patients diagnosed with DA-resistant prolactinomas between 1993-2017 in three medical centers. Resistance was defined as PRL levels above three times the upper limit of normal (ULN) despite a weekly dose of ≥2 mg cabergoline (CAB). Clinical and biochemical information, and response to treatment, were retrieved from medical records.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six patients were identified; 20 males. Of 25 macroadenomas, three were giant tumors (&gt;40 mm) and 15 (57.7%) were invasive. The mean age at diagnosis was 31.8 ± 14.9 years (range: 13-62). The median maximal CAB dose was 3.5 mg/week (IQR, 2.5-5). Half the patients received only CAB in escalating doses, nine received CAB and underwent transsphenoidal surgery, and four underwent surgery and radiotherapy in addition to CAB treatment. PRL levels at baseline between patients treated only with CAB and those operated were (91.6 [51.1-296.7] vs. 73.1 [22.6-170.9] XULN p = 0.355), and under maximal CAB dose PRL levels between patients treated only with CAB and those operated were similar (5.77 [1.27-11.27] vs 5.27 (2.9-26) XULN p = 0.317). At the last visit patients who received combined therapy achieved lower PRL levels than those treated with DA only (5.22 [1.7-21.6] vs 1.1 [0.44-3.99] XULN p = 0.017) PRL normalization was attained in seven patients and levels below 3 × ULN in fourteen patients; the overall response was 56%.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Resistant prolactinomas usually require a multi-modal treatment strategy. We were able to control 14/25 (56%) of resistant tumors.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Eshkoli</LastName>
            <ForeName>Tamar</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-2660-9311</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Soroka Medical Center, Beer-Sheva, Israel. esh.tamar@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ben-Gurion University of the Negev, Beer-Sheva, Israel. esh.tamar@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Fraenkel</LastName>
            <ForeName>Merav</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-9039-5565</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Soroka Medical Center, Beer-Sheva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zaid</LastName>
            <ForeName>Dana</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Diabetes, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Dayana</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-4033-9968</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Soroka Medical Center, Beer-Sheva, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoel</LastName>
            <ForeName>Uri</ForeName>
            <Initials>U</Initials>
            <Identifier Source="ORCID">0000-0003-3805-3565</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Soroka Medical Center, Beer-Sheva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsvetov</LastName>
            <ForeName>Gloria</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-2033-7300</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrine Institute, Rabin-Beilinson Medical Center, Petah-Tiqva, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorshtein</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Institute, Rabin-Beilinson Medical Center, Petah-Tiqva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goldbart</LastName>
            <ForeName>Adi</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-1682-6435</Identifier>
            <AffiliationInfo>
              <Affiliation>Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Greenman</LastName>
            <ForeName>Yona</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4923-488X</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Diabetes, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Shimon</LastName>
            <ForeName>Ilan</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-9188-3894</Identifier>
            <AffiliationInfo>
              <Affiliation>Endocrine Institute, Rabin-Beilinson Medical Center, Petah-Tiqva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Endocrine</MedlineTA>
        <NlmUniqueID>9434444</NlmUniqueID>
        <ISSNLinking>1355-008X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cabergoline</Keyword>
        <Keyword MajorTopicYN="N">Dopamine agonist</Keyword>
        <Keyword MajorTopicYN="N">Pituitary</Keyword>
        <Keyword MajorTopicYN="N">Prolactinoma</Keyword>
        <Keyword MajorTopicYN="N">Resistance</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>11</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35604631</ArticleId>
        <ArticleId IdType="doi">10.1007/s12020-022-03080-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s12020-022-03080-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>A. Tirosh, I. Shimon, Current approach to treatments for prolactinomas. Minerva Endocrinol. 41, 316–323 (2016)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26399371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A. Colao, S. Savastano, Medical treatment of prolactinomas. Nat. Rev. Endocrinol. 7, 267–278 (2011)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2011.37</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.beem.2019.101290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265–273 (2016)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2006.02562.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2010-1692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V. Vasilev, A.F. Daly, L. Vroonen, S. Zacharieva, A. Beckers, Resistant prolactinomas. J. Endocrinol. Invest 34, 312–316 (2011)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03347092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A. Colao, A. Di Sarno, M.L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in I patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85, 2247–2252 (2000)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10852458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331, 904–909 (1994)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199410063311403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518–2522 (1999)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.84.7.5810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721–4727 (2008)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2007-2758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M.E. Molitch, Management of medically refractory prolactinoma. J. Neurooncol 117, 421–428 (2014)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-013-1270-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>L. Vroonen, M.L. Jaffrain-Rea, P. Petrossians, G. Tamagno, P. Chanson, L. Vilar et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167, 651–662 (2012)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-12-0236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D. Maiter, Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109, 42–50 (2019)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000495775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>I. Pellegrini, R. Rasolonjanahary, G. Gunz, P. Bertrand, S. Delivet, C.P. Jedynak et al. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 69, 500–509 (1989)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem-69-3-500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V.Q. Passos, M.A. Fortes, D. Giannella-Neto, M.D. Bronstein, Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89, 163–170 (2009)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000156116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M.C. Oh, M.K. Aghi, Dopamine agonist–resistant prolactinomas. J. Neurosurg. 114, 1369–1379 (2011)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2010.11.JNS101369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R. Sari, M.A. Altinoz, E.B.K. Ozlu, A. Sav, A.E. Danyeli, O. Baskan, O. Er, I. Elmaci, Treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature. Horm. Metab. Res 53, 413–424 (2021)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-1525-2131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>F. Jian, Y. Sun, Q. Sun, B. Zhang, L. Bian, NEK2 regulates cellular proliferation and cabergoline sensitivity in pituitary adenomas. J. Cancer 12, 2083–2091 (2021)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.52937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Y. Rudman, H. Duskin-Bitan, Y. Manisterski, B. Pertzov, A. Akirov, H. Masri-Iraqi, I. Shimon, Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter? Clin. Endocrinol. (Oxf.) 95(4), 606–617 (2021)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.14541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>I. Shimon, E. Sosa, V. Mendoza, Y. Greenman, A. Tirosh, E. Espinosa et al. Giant prolactinomas larger than 60mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 9, 429–436 (2016)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-016-0723-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>H. Duskin-Bitan, I. Shimon, Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-019-01009-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K.J. Yagnik, D. Erickson, I. Bancos, J.L.D. Atkinson, G. Choby, M. Peris-Celda, Van, J.J. Gompel, Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24, 978–988 (2021)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-021-01188-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C.E. Stiles, G. Lloyd, S. Bhattacharyya, R.P. Steeds, K. Boomla, J.P. Bestwick et al. Incidence of cabergoline associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J. Clin. Endocrinol. Metab. 23, 106 (2021)</Citation>
        </Reference>
        <Reference>
          <Citation>V. Primeau, C. Raftopoulos, D. Maiter, Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. May 166(5), 779–86 (2012)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-11-1000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A.B. Moraes, C.M. Silva, L. Vieira Neto, M.R. Gadelha, Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. (Oxf.) 79, 447–456 (2013)</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12242</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
